Serum ROCK2, miR-300 and miR-450b-5p levels in two different clinical phenotypes of multiple sclerosis: Relation to patient disability and disease progression

Samar H. Ibrahim, Karim M. El-Mehdawy, Mae Seleem, Maha M. El-Sawalhi, Amira A. Shaheen

Research output: Contribution to journalArticlepeer-review

Abstract

Relapsing remitting multiple sclerosis (RRMS) is the most prevalent MS subtype. Years after disease onset, most of RRMS patients show transition into secondary progressive form (SPMS). Currently, no biomarkers are available for tracking disease progression. Here, we observed marked elevation of Rho-associated protein kinase 2 (ROCK2) along with significant downregulation of miRNAs 300 and 450b-5p expressions in the serum of 39 RRMS and 35 SPMS Egyptian patients compared to healthy controls. More pronounced alterations were found in SPMS versus RRMS patients. Our findings also suggest relations between elevated ROCK2 and reduced expression of both miRNAs with the degree of disability and disease progression. Notably, these biomarkers effectively discriminated RRMS from SPMS patients with miR-450b-5p showing the highest prognostic power.

Original languageEnglish (US)
Article number577356
JournalJournal of neuroimmunology
Volume347
DOIs
StatePublished - Oct 15 2020

Keywords

  • Disease progression
  • miRNA
  • ROCK2
  • RRMS
  • SPMS

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Neurology
  • Clinical Neurology

Fingerprint

Dive into the research topics of 'Serum ROCK2, miR-300 and miR-450b-5p levels in two different clinical phenotypes of multiple sclerosis: Relation to patient disability and disease progression'. Together they form a unique fingerprint.

Cite this